These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27959425)

  • 1. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
    Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
    Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC
    Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
    BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
    Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
    Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
    Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallic acid induces the apoptosis of human osteosarcoma cells in vitro and in vivo via the regulation of mitogen-activated protein kinase pathways.
    Liang CZ; Zhang X; Li H; Tao YQ; Tao LJ; Yang ZR; Zhou XP; Shi ZL; Tao HM
    Cancer Biother Radiopharm; 2012 Dec; 27(10):701-10. PubMed ID: 22849560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway.
    Nitta RT; Gholamin S; Feroze AH; Agarwal M; Cheshier SH; Mitra SS; Li G
    Oncogene; 2015 Jul; 34(28):3688-99. PubMed ID: 25241897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
    Di Maira G; Brustolon F; Bertacchini J; Tosoni K; Marmiroli S; Pinna LA; Ruzzene M
    Oncogene; 2007 Oct; 26(48):6915-26. PubMed ID: 17486073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear localization of the CK2α-subunit correlates with poor prognosis in clear cell renal cell carcinoma.
    Rabjerg M; Guerra B; Oliván-Viguera A; Mikkelsen ML; Köhler R; Issinger OG; Marcussen N
    Oncotarget; 2017 Jan; 8(1):1613-1627. PubMed ID: 27906674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.
    Kendall JJ; Chaney KE; Patel AV; Rizvi TA; Largaespada DA; Ratner N
    Oncotarget; 2016 Aug; 7(33):53191-53203. PubMed ID: 27448963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
    Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
    J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
    Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
    Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    Rowse AL; Gibson SA; Meares GP; Rajbhandari R; Nozell SE; Dees KJ; Hjelmeland AB; McFarland BC; Benveniste EN
    J Neurooncol; 2017 Apr; 132(2):219-229. PubMed ID: 28181105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.